Olezarsen sodium: clinical use

Prescribing considerations

• Confirm familial chylomicronaemia syndrome genetically and continue appropriate dietary management.
• Safety and efficacy have not been established in children or adolescents.
• Evidence is limited in severe renal impairment, end-stage renal disease, and moderate or severe hepatic impairment; use requires an individual benefit–risk assessment.
• Review clinical and biochemical response and reconsider treatment where meaningful benefit is not demonstrated.

Contraindications and cautions

• Hypersensitivity to olezarsen or any product excipient.

Monitoring

• Remain vigilant for acute or delayed hypersensitivity reactions.
• Consider individualised platelet, liver and renal monitoring, particularly where counts are already low or organ impairment is present; serious toxicity was not identified during development but cannot be excluded from class experience.
• Monitor triglyceride response and relevant clinical outcomes.

Clinical pharmacology

A GalNAc-conjugated antisense oligonucleotide targeting hepatic APOC3 mRNA. It is metabolised by nucleases rather than CYP enzymes, distributes mainly to the liver and kidney cortex, and has minimal urinary elimination as unchanged oligonucleotide.

Formulation and product differences

• A clear, colourless-to-yellow solution in a disposable single-use pre-filled pen for subcutaneous use only.
• The product is essentially sodium-free.
• Store refrigerated and protected from light. It may be kept in its original packaging at up to 30°C for up to six weeks; record the disposal date after removal from refrigeration.

Injection

Route: Parenteral

Strengths: 80 mg